{"id":"W2768649895","doi":"10.1016/s1470-2045(17)30716-7","title":"Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":529,"is_retracted":false,"has_abstract":true,"ca_institutions":"Jewish General Hospital; McGill University","funders":"Johnson and Johnson; F. Hoffmann-La Roche; Eli Lilly and Company","keywords":"Pertuzumab; Medicine; Trastuzumab; Trastuzumab emtansine; Docetaxel; Oncology; Internal medicine; Breast cancer; Carboplatin; Regimen; Neoadjuvant therapy; Metastatic breast cancer; Cancer; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001228867,0.0005741048,0.002064518,0.0001499826,0.000655012,0.0002564797,0.001190343,0.0003026223,0.0005009529],"category_scores_gemma":[0.0005617111,0.0003693966,0.00008591436,0.000227672,0.001088165,0.0003036011,0.0003595215,0.001088191,0.00002045146],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002941645,"about_ca_system_score_gemma":0.002510281,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004346227,"about_ca_topic_score_gemma":0.004473965,"domain_scores_codex":[0.9957668,0.0006100551,0.0007055121,0.0009502664,0.0007471818,0.001220228],"domain_scores_gemma":[0.9964132,0.0009439858,0.0005173766,0.001321225,0.0004035954,0.0004005923],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8591858,0.003741885,0.003915283,0.0001040146,0.0004803774,0.000352574,0.002836273,0.000007521877,0.000115688,0.00003590904,0.003260805,0.1259639],"study_design_scores_gemma":[0.8948277,0.01571845,0.07896309,0.0004696586,0.0003081653,0.0001029224,0.0004230189,0.001353138,0.00006084626,0.00001735987,0.007309026,0.0004465725],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.962174,0.0004813735,0.00002469492,0.02392821,0.0007957061,0.007617556,0.000427312,0.00005918563,0.004491955],"genre_scores_gemma":[0.9933774,0.00144626,0.0004870856,0.001628005,0.001305473,0.0009572378,0.0000874663,0.000120957,0.000590126],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1255174,"threshold_uncertainty_score":0.9998758,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09179359523436297,"score_gpt":0.4422125994061898,"score_spread":0.3504190041718268,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}